HLS Therapeutics (TSE:HLS) Hits New 52-Week Low – Should You Sell?

HLS Therapeutics Inc. (TSE:HLS)’s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as C$4.11 and last traded at C$4.00, with a volume of 4274 shares changing hands. The stock had previously closed at C$4.12.

HLS Therapeutics Stock Down 1.9%

The firm has a fifty day moving average of C$4.29 and a 200-day moving average of C$4.45. The company has a quick ratio of 1.01, a current ratio of 1.00 and a debt-to-equity ratio of 75.00. The firm has a market cap of C$126.35 million, a P/E ratio of -12.62 and a beta of -0.18.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings results on Friday, May 15th. The company reported C($0.10) earnings per share for the quarter. The company had revenue of C$17.88 million during the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. On average, equities research analysts anticipate that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.